WO2023133575A3 - Methods and systems for treating chronic itch conditions using digital therapeutics in combination with other therapies - Google Patents

Methods and systems for treating chronic itch conditions using digital therapeutics in combination with other therapies Download PDF

Info

Publication number
WO2023133575A3
WO2023133575A3 PCT/US2023/060356 US2023060356W WO2023133575A3 WO 2023133575 A3 WO2023133575 A3 WO 2023133575A3 US 2023060356 W US2023060356 W US 2023060356W WO 2023133575 A3 WO2023133575 A3 WO 2023133575A3
Authority
WO
WIPO (PCT)
Prior art keywords
systems
methods
chronic itch
therapies
combination
Prior art date
Application number
PCT/US2023/060356
Other languages
French (fr)
Other versions
WO2023133575A2 (en
Inventor
Steven BASTA
Simon Levy
Ann Harriet Montgomery
Noreen WATSON
Original Assignee
Mahana Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahana Therapeutics, Inc. filed Critical Mahana Therapeutics, Inc.
Publication of WO2023133575A2 publication Critical patent/WO2023133575A2/en
Publication of WO2023133575A3 publication Critical patent/WO2023133575A3/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Systems and methods are provided for treating, ameliorating, preventing, or reducing the likelihood of developing a chronic itch (pruritus) disorder, one or more of symptoms and comorbidities associated with the chronic itch disorder, and/or one or more side effects associated with therapeutic interventions for treating the chronic itch disorder using digital therapeutics. Further, systems and methods are provided for improving adherence to the therapeutic interventions and improving performance of the therapeutic interventions using digital therapeutics.
PCT/US2023/060356 2022-01-10 2023-01-10 Methods and systems for treating chronic itch conditions using digital therapeutics in combination with other therapies WO2023133575A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263298014P 2022-01-10 2022-01-10
US63/298,014 2022-01-10

Publications (2)

Publication Number Publication Date
WO2023133575A2 WO2023133575A2 (en) 2023-07-13
WO2023133575A3 true WO2023133575A3 (en) 2023-10-05

Family

ID=87074360

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/060356 WO2023133575A2 (en) 2022-01-10 2023-01-10 Methods and systems for treating chronic itch conditions using digital therapeutics in combination with other therapies

Country Status (1)

Country Link
WO (1) WO2023133575A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151671A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of cosmetic proteins and peptides
US20170119792A1 (en) * 2015-06-10 2017-05-04 Apex Laboratories Private Limited Methods and compositions for dermatological use comprising clobetasol and halobetasol and biopolymers
US20190083809A1 (en) * 2016-07-27 2019-03-21 Z2020, Llc Componentry and devices for light therapy delivery and methods related thereto
US20220028528A1 (en) * 2019-06-27 2022-01-27 Mahana Therapeutics, Inc. Methods and systems for treating health conditions using prescription digital therapeutics
WO2022086781A1 (en) * 2020-10-22 2022-04-28 Mahana Therapeutics, Inc. Methods and systems for treating health conditions using prescription digital therapeutics

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151671A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of cosmetic proteins and peptides
US20170119792A1 (en) * 2015-06-10 2017-05-04 Apex Laboratories Private Limited Methods and compositions for dermatological use comprising clobetasol and halobetasol and biopolymers
US20190083809A1 (en) * 2016-07-27 2019-03-21 Z2020, Llc Componentry and devices for light therapy delivery and methods related thereto
US20220028528A1 (en) * 2019-06-27 2022-01-27 Mahana Therapeutics, Inc. Methods and systems for treating health conditions using prescription digital therapeutics
WO2022086781A1 (en) * 2020-10-22 2022-04-28 Mahana Therapeutics, Inc. Methods and systems for treating health conditions using prescription digital therapeutics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MODI JUHI: "What Medications Can Cause Fatigue?", BUZZRX, 9 December 2021 (2021-12-09), XP093099174, Retrieved from the Internet <URL:https://www.buzzrx.com/blog/what-medications-can-cause-fatigue> [retrieved on 20231108] *

Also Published As

Publication number Publication date
WO2023133575A2 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
JP2020515581A5 (en)
WO2016161055A3 (en) Methods of treating cancers, autoimmune disorders, and other conditions associated with chronic inflammation
WO2023133575A3 (en) Methods and systems for treating chronic itch conditions using digital therapeutics in combination with other therapies
Pisoni et al. Mycophenolate mofetil and systemic lupus erythematosus: an overview
WO2013072451A3 (en) System and method for highly scalable decentralized and low contention transactional processing x
Benucci et al. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis
Hagberg et al. The changing panorama of infantile hydrocephalus and cerebral palsy over forty years—a Swedish survey
Kanazawa Anticholinergic agents in asthma: chronic bronchodilator therapy, relief of acute severe asthma, reduction of chronic viral inflammation and prevention of airway remodeling
MX2020013301A (en) Methods and compositions for preventing or treating calciphylaxis.
WO2023141376A3 (en) Methods and systems for treating respiratory conditions using digital therapeutics in combination with other therapies
Niazi et al. A review of extracorporeal blood purification techniques for the treatment of critically ill coronavirus disease 2019 patients
Ghannoum et al. Extracorporeal treatment for methotrexate poisoning: systematic review and recommendations from the EXTRIP workgroup
MX2021003957A (en) Intermediate film for laminated glass and laminated glass.
高芷華 et al. Life expectancy, expected years of life lost and survival of hemodialysis and peritoneal dialysis patients
WO2022027237A1 (en) Application of quizartinib as necroptosis inhibitor
Bottari et al. Hybrid blood purification strategy in pediatric septic shock
WO2021003468A3 (en) Recombinant sialidases and methods of using the same
WO2005123772A3 (en) Anti-cancer therapy
MX2022011833A (en) Intermediate film for laminated glass and laminated glass.
Boffini et al. Does everolimus associated with a low dose of cyclosporine in long-term cardiac transplant recipients improve renal function? Initial experience
Kowdley et al. Adding rifaximin to lactulose increased reversal and decreased mortality in hepatic encephalopathy
Wilsmann‐Theis et al. Low‐dose methotrexate–a therapeutical kick in TNF‐alpha antagonist treatment for recalcitrant psoriasis vulgaris
Sönmez Failed Nabucco project and its implications
D’Amico Economic Implications of Nutritional Treatment of Chronic Renal Failure
Barak Dramatic Improvement in Dyspnea in A Non-Small Cell Lung Cancer Patient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23737835

Country of ref document: EP

Kind code of ref document: A2